Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Surendar Basaveni"'
Autor:
Aarti Sevilimedu, Marina Rajadurai, Pushkar Kulkarni, Uday Saxena, Raghavender Medishetti, Surendar Basaveni, Swapna Yellanki
Publikováno v:
Current Nanomedicine. 9:173-181
Background: Plasma pharmacokinetic (PK) properties of oral or injectable drugs dictate whether the drug is clinically viable or not. Poor PK properties often result in termination of the development of the drug. Optimizing PK properties of drugs is a
Autor:
Uday Saxena, Surendar Basaveni, Pushkar Kulkarni, Swapna Yellanki, Aarti Sevilimedu, Marina Rajadurai, Raghavender Medishetti
Publikováno v:
Drug Delivery and Translational Research. 8:1450-1459
Lung cancer is the single largest cause of cancer related deaths in the world. Current treatments include surgery, radiation therapy, chemotherapy using cytotoxic drugs, and monoclonal antibodies. Such treatments have limited efficacy due to diverse
Autor:
Marina Rajadurai, Raghavender Medishetti, Pushkar Kulkarni, Swapna Yellanki, Uday Saxena, Surendar Basaveni, Aarti Sevilimedu
Publikováno v:
Current Nanomedicine. 11:139-139
Due to an editorial oversight, we would like to apologize for an error that occurred in the print version of an article entitled “Double PEGylation Significantly Improves Pharmacokinetic Properties of Irinotecan Containing Nanoparticles in a Zebraf